Assessment of vitamin D oral supplementationon on insulin resistance, visceral fat and adiponectin in women with polycystic ovary syndrome and hypovitaminosis D

Assessment of vitamin D oral supplementation on insulin resistance, visceral fat and adiponectin in women with polycystic ovary syndrome and hypovitaminosis D

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016101030248N1

Enrollment

Registered

2016-11-17

Start date

2016-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome

Interventions

Intervention 1: Intervention: 8 vitamin D3 capsule 50000 IU during 2 month (1 capsule in the week after lunch). Intervention 2: Control: 8 placebo capsule(Paraffinedible) during 2 month (1 capsule in

Treatment - Drugs

Placebo

Intervention: 8 vitamin D3 capsule 50000 IU during 2 month (1 capsule in the week after lunch)

Control: 8 placebo capsule(Paraffinedible) during 2 month (1 capsule in the week after lunch)

Eligibility

Sex/Gender

Female

Age

20 Years to 38 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Women with pcos according rotterdom criteria; Vitamin D deficiency ( x=<20 ng); OCPs consumer; Age between 20 to 38 Exclude criteria: Under 20 and over 38 years old; Neoplastic disorders; hepatic; renal; cardiovascular; malabsorptive and pregnancy; Those who consume vitamin D and taking antidiabetic drugs; People who follow a special diet pattern had specific physical activity

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: before intervention-after intervention (2 month later). Method of measurement: insulin resistance: HOMA-IR, HOMA-B ,QUICKI.;Visceral fat. Timepoint: before intervention-after intervention(2 month later). Method of measurement: visceral fat :BIA(Inbody 770).;Adiponectin. Timepoint: before intervention-after intervention(2 month later). Method of measurement: Adiponectin.: serum adiponectin.	—

Measure

Time frame

Insulin resistance. Timepoint: before intervention-after intervention (2 month later). Method of measurement: insulin resistance: HOMA-IR, HOMA-B ,QUICKI.;Visceral fat. Timepoint: before intervention-after intervention(2 month later). Method of measurement: visceral fat :BIA(Inbody 770).;Adiponectin. Timepoint: before intervention-after intervention(2 month later). Method of measurement: Adiponectin.: serum adiponectin.

—

Secondary

Measure	Time frame
Sun exposure and physical activity. Timepoint: during intervention. Method of measurement: The questionnaire sunlight.;Diet. Timepoint: week 4-6-8. Method of measurement: 24-hour recalls.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Sakineh Nouri Saeidlou

Urmia University of Medical Sciences

saeedlou2003@yahoo.com; nourisaeidlou_s@umsu.ac.ir+98 44 3276 6825

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026